Oligonucleotide Synthesis Market Analysis By Industry Share, Merger, Acquisition, Size Estimation, New Investment Opportunities, Statis
9:55 am
AVEO Pharmaceuticals with ticker code (AVEO) now have 4 analysts covering the stock. The analyst consensus points to a rating of ‘Strong Buy’. The range between the high target price and low target price is between 17 and 7 with a mean TP of 11.25. Now with the previous closing price of 5.52 this indicates there is a potential upside of 103.8%. The 50 day MA is 5.53 and the 200 moving average now moves to 5.42. The market capitalisation for the company is $165m. Company Website: http://www.aveooncology.com
AVEO Pharmaceuticals, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical needs. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase III TIVO-3 trial of tivozanib for the treatment of RCC;